↓ Skip to main content

Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12® Lactobacillus rhamnosus…

Overview of attention for article published in Frontiers in oncology, August 2023
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12® Lactobacillus rhamnosus LGG® in colorectal cancer patients
Published in
Frontiers in oncology, August 2023
DOI 10.3389/fonc.2023.1168654
Pubmed ID
Authors

Michal Mego, Radoslav Danis, Jozef Chovanec, Silvia Jurisova, Branislav Bystricky, Stefan Porsok, Peter Konkolovsky, Vladimir Vaclav, Maria Wagnerova, Marian Streško, Bibiana Brezinova, Mária Rečková, Dagmar Sutekova, Natalia Pazderova, Mária Novisedlakova, Eva Zomborska, Sona Ciernikova, Daniela Svetlovska, Lubos Drgona

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 17%
Student > Bachelor 1 17%
Lecturer 1 17%
Student > Master 1 17%
Unknown 2 33%
Readers by discipline Count As %
Medicine and Dentistry 2 33%
Agricultural and Biological Sciences 1 17%
Unspecified 1 17%
Unknown 2 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2023.
All research outputs
#23,513,156
of 26,180,352 outputs
Outputs from Frontiers in oncology
#16,431
of 22,922 outputs
Outputs of similar age
#308,937
of 366,332 outputs
Outputs of similar age from Frontiers in oncology
#667
of 1,027 outputs
Altmetric has tracked 26,180,352 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,922 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 366,332 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,027 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.